RecruitingNCT07099443

Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia

Sponsor

Nantes University Hospital

Enrollment

60 participants

Start Date

Oct 9, 2025

Study Type

OBSERVATIONAL

Conditions

Chronic Lymphocytic Leukemia BTK Degraders

Summary

The aim of the REBELLE cohort - bio-collection is to collect samples from patients with Chronic Lymphocytic Leukemia candidates or those exposed to BTK degraders to evaluate the mechanisms of resistance to these new molecules. To do this, an additional blood or bone marrow sample to those planned in the context of patient care or a residual lymph node biopsy sample will be collected after signing consent.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is examining the biological and genetic reasons why some patients with chronic lymphocytic leukemia (CLL — a type of blood cancer) stop responding to two key types of targeted therapy: BTK inhibitors (such as ibrutinib) and BCL-2 inhibitors (such as venetoclax). The goal is to find new treatment strategies for this difficult-to-treat group. **You may be eligible if...** - You have CLL that is no longer responding to both a BTK inhibitor and a BCL-2 inhibitor - OR you have known genetic mutations that cause resistance to these drugs - You have provided informed consent - You are covered by a social security health insurance plan (in France) **You may NOT be eligible if...** - You are a minor (under 18) - You are an adult under legal guardianship - You are a legally protected person Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNon-Interventional Sample Collection and Analysis

This study is observational. Biological samples are collected as part of standard care or for research purposes and analyzed to characterize resistance mechanisms. No treatment or intervention is administered as part of the study protocol.

Locations(14)

CHU de Angers

Angers, France

CHU de Bordeaux

Bordeaux, France

Institut Bergonié

Bordeaux, France

CHU de Clermont-Ferrand

Clermont-Ferrand, France

CHD Vendée

La Roche-sur-Yon, France

Centre Léon Bernard

Lyon, France

Institut Paoli-Calmettes (Marseille)

Marseille, France

CHU de Montpellier

Montpellier, France

CH Régional Universitaire de Nancy

Nancy, France

University Hospital

Nantes, France

Hôpital Avicenne (AP-HP)

Paris, France

Hôpital Universitaire Pitié Salpêtrière de Paris

Paris, France

CHU de Poitiers

Poitiers, France

Centre Henri-Becquerel de Rouen

Rouen, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07099443

Related Trials

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

NCT04269902629 locations

A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG

NCT067929942 locations

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

NCT06136559196 locations

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

NCT06943872167 locations

Understanding Chronic Lymphocytic Leukemia

NCT040285311 location